Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 28, 2017
Reporting Period: Event-based report regarding regulatory approval received on December 28, 2017.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The document focuses exclusively on a regulatory milestone.
Material Changes
Regulatory Approval: On December 28, 2017, the Company received notice from the United States Food and Drug Administration (FDA) permitting the marketing of the dermaPACE® System. This represents a significant operational milestone enabling commercialization of the product.
Guidance, Outlook, and Risks
- Management Commentary: The Company issued a press release on December 29, 2017, and scheduled a conference call for January 2, 2018, to discuss the FDA letter and its implications.
- Forward-Looking Statements: The filing includes standard cautionary language regarding forward-looking statements, noting that actual results may differ due to risks and uncertainties.
- Risks: Investors are directed to the "Risk Factors" section of the Company's Annual Report on Form 10-K for a detailed discussion of risks that could affect future performance.
Investor Verification Checklist
- Verify the specific terms and conditions of the FDA marketing permission for the dermaPACE® System in Exhibit 99.1.
- Review the press release (Exhibit 99.2) for details on the commercialization timeline and strategy.
- Check the Company's Form 10-K for historical financial performance and risk factors not detailed in this 8-K.
- Confirm the outcome of the conference call held on January 2, 2018, regarding the implications of the FDA notice.